<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<meta name="generator" content="Hugo 0.102.3" />


<title>Publications - Keaven M. Anderson</title>
<meta property="og:title" content="Publications - Keaven M. Anderson">


  <link href='/favicon.ico' rel='icon' type='image/x-icon'/>



  







<link rel="stylesheet" href="/css/fonts.css" media="all">
<link rel="stylesheet" href="/css/main.css" media="all">



  </head>
  <body>
    <div class="wrapper">
      <header class="header">
        <nav class="nav">
  <a href="/" class="nav-logo">
    <img src="/images/logo.png"
         width="50"
         height="50"
         alt="Logo">
  </a>

  <ul class="nav-links">
    
    <li><a href="/publications/">Publications</a></li>
    
    <li><a href="/software/">Software</a></li>
    
    <li><a href="/talks/">Talks</a></li>
    
    <li><a href="https://github.com/keaven">GitHub</a></li>
    
    <li><a href="https://www.linkedin.com/in/keaven-anderson-09aa7538/">LinkedIn</a></li>
    
  </ul>
</nav>

      </header>


<main class="content" role="main">

  <article class="article">
    

    <h1 class="article-title">Publications</h1>

    

    <div class="article-content">
      


<!-- After the .bib file is updated, knit this Rmd to update publications.html, then commit and push both the .bib and .html -->
<p>(Under construction)</p>
<div id="recent" class="section level2">
<h2>Recent</h2>
<p>Mukhopadhyay, P., Ye, J., Anderson, K. M., Roychoudhury, S., Rubin, E. H., Halabi, S., &amp; Chappell, R. J. (2022). Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis. JAMA oncology.</p>
<p>Anderson, K. M., Guo, Z., Zhao, J., &amp; Sun, L. Z. (2022). A unified framework for weighted parametric group sequential design. Biometrical Journal.</p>
<p>Chen, T. Y., Zhao, J., Sun, L., &amp; Anderson, K. M. (2021). Multiplicity for a group sequential trial with biomarker subpopulations. Contemporary Clinical Trials, 101, 106249.</p>
<p>Bautista, O., &amp; Anderson, K. (2021). Sample Size Estimation and Power Analysis: Time to Event Data. In Handbook of Statistical Methods for Randomized Controlled Trials (pp. 275-300). Chapman and Hall/CRC.</p>
<p>Roychoudhury, S., Anderson, K. M., Ye, J., &amp; Mukhopadhyay, P. (2021). Robust design and analysis of clinical trials with nonproportional hazards: a straw man guidance from a cross-pharma working group. Statistics in Biopharmaceutical Research, 1-15.</p>
<p>Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., … &amp; Working, C. P. N. P. H. (2020). Rejoinder to letter to the editor “The hazards of period specific and weighted hazard ratios”. Statistics in Biopharmaceutical Research, 12(4), 520.</p>
<p>Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., … &amp; Cross-Pharma Non-Proportional Hazards Working Group. (2020). Alternative analysis methods for time to event endpoints under nonproportional hazards: a comparative analysis. Statistics in Biopharmaceutical Research, 12(2), 187-198.</p>
<p>Tian, L., Jin, H., Uno, H., Lu, Y., Huang, B., Anderson, K. M., &amp; Wei, L. J. (2020). On the empirical choice of the time window for restricted mean survival time. Biometrics, 76(4), 1157-1166.</p>
<p>León, L. F., Lin, R., &amp; Anderson, K. M. (2020). On weighted log-rank combination tests and companion Cox model estimators. Statistics in Biosciences, 12(2), 225-245.</p>
<p>Turner, D. C., Kondic, A. G., Anderson, K. M., Robinson, A. G., Garon, E. B., Riess, J. W., … &amp; Stone, J. A. (2018). Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic ClearancePembrolizumab PK/PD Confounding and Cancer Cachexia. Clinical Cancer Research, 24(23), 5841-5849.</p>
<p>Joseph, Richard W., et al. “Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab: Impact of Baseline Tumor Size on Outcomes in Melanoma.” <em>Clinical Cancer Research</em> <em>24.20</em> (2018): 4960-4967.</p>
<p>Chen, Cong, et al. “A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development.” Contemporary clinical trials 64 (2018): 238-242.</p>
</div>
<div id="section" class="section level2">
<h2>2021</h2>
<ul>
<li>Roychoudhury, S., Anderson, K. M., Ye, J., &amp; Mukhopadhyay, P.
(2021). Robust design and analysis of clinical trials with
nonproportional hazards: A straw man guidance from a cross-pharma
working group. <em>Statistics in Biopharmaceutical Research</em>, 1–15.</li>
</ul>
</div>
<div id="section-1" class="section level2">
<h2>2020</h2>
<ul>
<li><p>Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T.,
Huang, B., Leon, L. F., Liao, J. J., Liu, R., Luo, X., et al. (2020).
Alternative analysis methods for time to event endpoints under
nonproportional hazards: A comparative analysis. <em>Statistics in
Biopharmaceutical Research</em>, <em>12</em>(2), 187–198.</p></li>
<li><p>Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T.,
Huang, B., Leon, L. F., Liao, J. J., Liu, R., Luo, X., et al. (2020).
Rejoinder to letter to the editor “the hazards of period specific and
weighted hazard ratios”. <em>Statistics in Biopharmaceutical Research</em>,
<em>12</em>(4), 520.</p></li>
<li><p>Tian, L., Jin, H., Uno, H., Lu, Y., Huang, B., Anderson, K. M., &amp;
Wei, L. (2020). On the empirical choice of the time window for
restricted mean survival time. <em>Biometrics</em>, <em>76</em>(4), 1157–1166.</p></li>
</ul>
</div>
<div id="section-2" class="section level2">
<h2>2018</h2>
<ul>
<li><p>Bohula, E. A., Scirica, B. M., Inzucchi, S. E., McGuire, D. K.,
Keech, A. C., Smith, S. R., Kanevsky, E., Murphy, S. A., Leiter, L. A.,
Dwyer, J. P., et al. (2018). Effect of lorcaserin on prevention and
remission of type 2 diabetes in overweight and obese patients
(CAMELLIA-TIMI 61): A randomised, placebo-controlled trial. <em>The
Lancet</em>, <em>392</em>(10161), 2269–2279.</p></li>
<li><p>Chen, C., Anderson, K., Mehrotra, D. V., Rubin, E. H., &amp; Tse, A.
(2018). A 2-in-1 adaptive phase 2/3 design for expedited oncology drug
development. <em>Contemporary Clinical Trials</em>, <em>64</em>, 238–242.</p></li>
<li><p>Joseph, R. W., Elassaiss-Schaap, J., Kefford, R., Hwu, W.-J.,
Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, O.,
Robert, C., et al. (2018). Baseline tumor size is an independent
prognostic factor for overall survival in patients with melanoma treated
with Pembrolizumab. <em>Clinical Cancer Research</em>, <em>24</em>(20), 4960–4967.</p></li>
<li><p>Joseph, R. W., Elassaiss-Schaap, J., Kefford, R., Hwu, W.-J.,
Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, O.,
Robert, C., et al. (2018). Correction: Baseline tumor size is an
independent prognostic factor for overall survival in patients with
melanoma treated with Pembrolizumab. <em>Clinical Cancer Research</em>,
<em>24</em>(23), 6098–6098.</p></li>
<li><p>Turner, D. C., Kondic, A. G., Anderson, K. M., Robinson, A. G.,
Garon, E. B., Riess, J. W., Jain, L., Mayawala, K., Kang, J.,
Ebbinghaus, S. W., et al. (2018). Pembrolizumab exposure–response
assessments challenged by association of cancer cachexia and catabolic
ClearancePembrolizumab PK/PD confounding and cancer cachexia. <em>Clinical
Cancer Research</em>, <em>24</em>(23), 5841–5849.</p></li>
</ul>
</div>
<div id="section-3" class="section level2">
<h2>2014</h2>
<ul>
<li><p>He, W., Pinheiro, J., &amp; Kuznetsova, O. M. (2014). <em>Practical
considerations for adaptive trial design and implementation</em>. Springer.</p></li>
<li><p>Joseph, R. W., Elassaiss-Schaap, J., Wolchok, J. D., Joshua, A. M.,
Ribas, A., Hodi, F. S., Hamid, O., Robert, C., Daud, A., Hwu, W.-J.,
Kefford, R., Hersey, P., Weber, J. S., Patnaik, A., De Alwis, D. P.,
Perrone, A. M., Kang, S. P., Ebbinghaus, S., Anderson, K. M., &amp;
Gangadhar, T. C. (2014). Baseline tumor size as an independent
prognostic factor for overall survival in patients with metastatic
melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.
<em>Journal of Clinical Oncology</em>, <em>32</em>(15_suppl), 3015–3015.</p></li>
</ul>
</div>
<div id="section-4" class="section level2">
<h2>2012</h2>
<ul>
<li><p>He, W., Kuznetsova, O. M., Harmer, M., Leahy, C., Anderson, K.,
Dossin, N., Li, L., Bolognese, J., Tymofyeyev, Y., &amp; Schindler, J.
(2012). Practical considerations and strategies for executing adaptive
clinical trials. <em>Drug Information Journal: DIJ/Drug Information
Association</em>, <em>46</em>(2), 160–174.</p></li>
<li><p>Liu, Q., Li, G., Anderson, K. M., &amp; Lim, P. (2012). On efficient
two-stage adaptive designs for clinical trials with sample size
adjustment. <em>Journal of Biopharmaceutical Statistics</em>, <em>22</em>(4), 617–640.</p></li>
</ul>
</div>
<div id="section-5" class="section level2">
<h2>2011</h2>
<ul>
<li>Rubin, E. H., Anderson, K. M., &amp; Gause, C. K. (2011). The BATTLE
trial: A bold step toward improving the efficiency of biomarker-based
drug development. <em>Cancer Discovery</em>, <em>1</em>(1), 17–20.</li>
</ul>
</div>
<div id="section-6" class="section level2">
<h2>2010</h2>
<ul>
<li><p>Anderson, K. M., &amp; Clark, J. B. (2010). Fitting spending functions.
<em>Statistics in Medicine</em>, <em>29</em>(3), 321–327.</p></li>
<li><p>Gallo, P., Anderson, K., Chuang-Stein, C., Dragalin, V., Gaydos,
B., Krams, M., &amp; Pinheiro, J. (2010). Viewpoints on the FDA draft
adaptive designs guidance from the PhRMA working group. <em>Journal of
Biopharmaceutical Statistics</em>, <em>20</em>(6), 1115–1124.</p></li>
</ul>
</div>
<div id="section-7" class="section level2">
<h2>2009</h2>
<ul>
<li>Gaydos, B., Anderson, K. M., Berry, D., Burnham, N., Chuang-Stein,
C., Dudinak, J., Fardipour, P., Gallo, P., Givens, S., Lewis, R., et al.
(2009). Good practices for adaptive clinical trials in pharmaceutical
product development. <em>Drug Information Journal</em>, <em>43</em>(5), 539–556.</li>
</ul>
</div>
<div id="section-8" class="section level2">
<h2>2008</h2>
<ul>
<li><p>Liu, Q., &amp; Anderson, K. M. (2008). On adaptive extensions of group
sequential trials for clinical investigations. <em>Journal of the American
Statistical Association</em>, <em>103</em>(484), 1621–1630.</p></li>
<li><p>Liu, Q., &amp; Anderson, K. (2008). Theory of inference for adaptively
extended group sequential designs with applications in clinical trials.
<em>Journal of the American Statistical Association, Supplemental Archive</em>.</p></li>
</ul>
</div>
<div id="section-9" class="section level2">
<h2>2007</h2>
<ul>
<li><p>Anderson, K. M. (2007). Optimal spending functions for asymmetric
group sequential designs. <em>Biometrical Journal: Journal of Mathematical
Methods in Biosciences</em>, <em>49</em>(3), 337–345.</p></li>
<li><p>Cohen, Y. C., Liu, K. S., Heyden, N. L., Carides, A. D., Anderson,
K. M., Daifotis, A. G., &amp; Gann, P. H. (2007). Detection bias due to the
effect of finasteride on prostate volume: A modeling approach for
analysis of the Prostate Cancer Prevention Trial. <em>Journal of the
National Cancer Institute</em>, <em>99</em>(18), 1366–1374.</p></li>
</ul>
</div>
<div id="section-10" class="section level2">
<h2>2006</h2>
<ul>
<li><p>Chuang-Stein, C., Anderson, K., Gallo, P., &amp; Collins, S. (2006).
Sample size reestimation: A review and recommendations. <em>Drug
Information Journal: DIJ/Drug Information Association</em>, <em>40</em>(4),
475–484.</p></li>
<li><p>Gallo, P., Chuang-Stein, C., Dragalin, V., Gaydos, B., Krams, M., &amp;
Pinheiro, J. (2006). Adaptive designs in clinical drug development—an
executive summary of the PhRMA working group. <em>Journal of
Biopharmaceutical Statistics</em>, <em>16</em>(3), 275–283.</p></li>
</ul>
</div>
<div id="section-11" class="section level2">
<h2>2004</h2>
<ul>
<li>Liu, Q., Anderson, K. M., &amp; Pledger, G. W. (2004). Benefit–risk
evaluation of multi-stage adaptive designs. <em>Sequential Analysis</em>,
<em>23</em>(3), 317–331.</li>
</ul>
</div>
<div id="section-12" class="section level2">
<h2>2002</h2>
<ul>
<li><p>Antman, E. M., Cooper, H., Gibson, C., Lemos, J. A. de, McCabe, C.,
Giugliano, R., Coussement, P., Murphy, S., Scherer, J., Anderson, K., et
al. (2002). Determinants of improvement in epicardial flow and
myocardial perfusion for ST elevation myocardial infarction. Insights
from TIMI 14 and InTIME-II. <em>European Heart Journal</em>, <em>23</em>(12), 928–933.</p></li>
<li><p>Kereiakes, D. J., Lincoff, A. M., Anderson, K. M., Achenbach, R.,
Patel, K., Barnathan, E., Califf, R. M., &amp; Topol, E. J. (2002).
Abciximab survival advantage following percutaneous coronary
intervention is predicted by clinical risk profile. <em>American Journal of
Cardiology</em>, <em>90</em>(6), 628–630.</p></li>
</ul>
</div>
<div id="section-13" class="section level2">
<h2>2001</h2>
<ul>
<li><p>Akkerhuis, K. M., Deckers, J. W., Lincoff, A. M., Tcheng, J. E.,
Boersma, E., Anderson, K., Balog, C., Califf, R. M., Topol, E. J., &amp;
Simoons, M. L. (2001). Risk of stroke associated with abciximab among
patients undergoing percutaneous coronary intervention. <em>JAMA</em>,
<em>286</em>(1), 78–82.</p></li>
<li><p>Anderson, K. M., Califf, R. M., Stone, G. W., Neumann, F.-J.,
Montalescot, G., Miller, D. P., Ferguson, J. J., Willerson, J. T.,
Weisman, H. F., &amp; Topol, E. J. (2001). Long-term mortality benefit with
abciximab in patients undergoing percutaneous coronary intervention.
<em>Journal of the American College of Cardiology</em>, <em>37</em>(8), 2059–2065.</p></li>
</ul>
</div>
<div id="section-14" class="section level2">
<h2>2000</h2>
<ul>
<li><p>Antman, E. M., Gibson, C., Lemos, J. A. de, Giugliano, R., McCabe,
C., Coussement, P., Menown, I., Nienaber, C., Rehders, T., Frey, M., et
al. (2000). Combination reperfusion therapy with abciximab and reduced
dose reteplase: Results from TIMI 14. <em>European Heart Journal</em>,
<em>21</em>(23), 1944–1953.</p></li>
<li><p>Lemos, J. A. de, Antman, E. M., Gibson, C. M., McCabe, C. H.,
Giugliano, R. P., Murphy, S. A., Coulter, S. A., Anderson, K., Scherer,
J., Frey, M. J., et al. (2000). Abciximab improves both epicardial flow
and myocardial reperfusion in ST-elevation myocardial infarction:
Observations from the TIMI 14 trial. <em>Circulation</em>, <em>101</em>(3), 239–243.</p></li>
<li><p>The Abciximab in Ischemic Stroke Investigators. (2000). Abciximab
in acute ischemic stroke: A randomized, double-blind,
placebo-controlled, dose-escalation study. <em>Stroke</em>, <em>31</em>(3), 601–609.</p></li>
<li><p>Kereiakes, D. J., Berkowitz, S. D., Lincoff, A. M., Tcheng, J. E.,
Wolski, K., Achenbach, R., Melsheimer, R., Anderson, K., Califf, R. M.,
&amp; Topol, E. J. (2000). Clinical correlates and course of
thrombocytopenia during percutaneous coronary intervention in the era of
abciximab platelet glycoprotein IIb/IIIa blockade. <em>American Heart
Journal</em>, <em>140</em>(1), 74–80.</p></li>
<li><p>Lincoff, A. M., Mark, D. B., Tcheng, J. E., Califf, R. M., Bala, M.
V., Anderson, K. M., Davidson-Ray, L., Knight, J. D., Cabot, C. F., &amp;
Topol, E. J. (2000). Economic assessment of platelet glycoprotein
IIb/IIIa receptor blockade with abciximab and low-dose heparin during
percutaneous coronary revascularization: Results from the EPILOG
randomized trial. <em>Circulation</em>, <em>102</em>(24), 2923–2929.</p></li>
</ul>
</div>
<div id="section-15" class="section level2">
<h2>1999</h2>
<ul>
<li><p>Antman, E. M., Giugliano, R. P., Gibson, C. M., McCabe, C. H.,
Coussement, P., Kleiman, N. S., Vahanian, A., Adgey, A. J., Menown, I.,
Rupprecht, H.-J., et al. (1999). Abciximab facilitates the rate and
extent of thrombolysis: Results of the thrombolysis in myocardial
infarction (TIMI) 14 trial. <em>Circulation</em>, <em>99</em>(21), 2720–2732.</p></li>
<li><p>Lincoff, A. M., Tcheng, J. E., Califf, R. M., Kereiakes, D. J.,
Kelly, T. A., Timmis, G. C., Kleiman, N. S., Booth, J. E., Balog, C.,
Cabot, C. F., et al. (1999). Sustained suppression of ischemic
complications of coronary intervention by platelet GP IIb/IIIa blockade
with abciximab: One-year outcome in the EPILOG trial. <em>Circulation</em>,
<em>99</em>(15), 1951–1958.</p></li>
<li><p>Topol, E. J., Mark, D. B., Lincoff, A. M., Cohen, E., Burton, J.,
Kleiman, N., Talley, D., Sapp, S., Booth, J., Cabot, C. F., et al.
(1999). Outcomes at 1 year and economic implications of platelet
glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting:
Results from a multicentre randomised trial. <em>The Lancet</em>, <em>354</em>(9195),
2019–2024.</p></li>
</ul>
</div>
<div id="section-16" class="section level2">
<h2>1998</h2>
<ul>
<li><p>Antman, E., Giugliano, R., McCabe, C., Gibson, M., Adgey, A.,
Ghali, M., Coussement, P., Anderson, K., Scherer, J., Van de Werf, F.,
et al. (1998). Abciximab (ReoPro) potentiates thrombolysis in ST
elevation myocardial infarction: Results of TIMI 14 trial. <em>Journal of
the American College of Cardiology</em>, <em>31</em>(2SA), 191A–191A.</p></li>
<li><p>Gibson, M., Giugliano, R., Anderson, K., Scherer, J., McCabe, C., &amp;
Antman, E. (1998). Abciximab enhances thrombolysis: A comparison of
abciximab alone versus abciximab plus low dose thrombolytics using the
corrected TIMI frame count. <em>Circulation</em>, <em>98</em>, 559–560.</p></li>
<li><p>Kereiakes, D. J., Lincoff, A. M., Miller, D. P., Tcheng, J. E.,
Cabot, C. F., Anderson, K. M., Weisman, H. F., Califf, R. M., &amp; Topol,
E. J. (1998). Abciximab therapy and unplanned coronary stent deployment:
Favorable effects on stent use, clinical outcomes, and bleeding
complications. <em>Circulation</em>, <em>97</em>(9), 857–864.</p></li>
<li><p>Kleiman, N. S., Lincoff, A. M., Kereiakes, D. J., Miller, D. P.,
Aguirre, F. V., Anderson, K. M., Weisman, H. F., Califf, R. M., &amp; Topol,
E. J. (1998). Diabetes mellitus, glycoprotein IIb/IIIa blockade, and
heparin: Evidence for a complex interaction in a multicenter trial.
<em>Circulation</em>, <em>97</em>(19), 1912–1920.</p></li>
<li><p>Koreiakos, D., Lincoff, A., Simoons, M., deBoer, M., Tcheng, J.,
Vahanian, A., Anderson, K., Weisman, H., Califf, R., &amp; Topol, E. (1998).
Complementarity of stenting and abciximab for percutaneous coronary
intervention. <em>Journal of the American College of Cardiology</em>, <em>31</em>,
54–54.</p></li>
</ul>
</div>
<div id="section-17" class="section level2">
<h2>1997</h2>
<ul>
<li><p>Aguirre, F., Simoons, M., Ferguson, J., FitzPatrick, S., Anderson,
K., Kern, M., &amp; Tcheng, J. (1997). Impact of contrast media on clinical
outcomes following percutaneous coronary interventions with platelet
glycoprotein IIb/IIIa inhibition: Meta-analysis of clinical trials with
abciximab. <em>Circulation</em>, <em>96</em>, 898–898.</p></li>
<li><p>CAPTURE Investigators and others. (1997). Randomized
placebo-controlled trial of abciximab before and during coronary
intervention in refractory angina: The CAPTURE study. <em>Lancet</em>, <em>349</em>,
1429–1435.</p></li>
<li><p>The EPILOG Investigators. (1997). Platelet glycoprotein IIb/IIIa
receptor blockade and low-dose heparin during percutaneous coronary
revascularization. <em>New England Journal of Medicine</em>, <em>336</em>(24),
1689–1697.</p></li>
<li><p>Gold, H., Kereiakes, D., Dinsmore, R., Martin, L., Lausten, D.,
Broderick, T., Anderson, K., Garabedian, H., &amp; Leinbach, R. (1997). A
randomized, placebo-controlled crossover trial of ReoPro alone or
combined with low-dose plasminogen activator for coronary reperfusion in
patients with acute myocardial infarction: Preliminary results.
<em>Circulation</em>, <em>96</em>, 2649–2649.</p></li>
<li><p>Lincoff, A., Tcheng, J., Califf, R., Cabot, C., Miller, D., Booth,
J., Montague, E., Anderson, K., &amp; Topol, E. (1997). Abciximab (<span class="nocase">c7E3 Fab</span>, ReoPro) with reduced heparin dosing
during coronary intervention: Final results of the EPILOG trial.
<em>Journal of the American College of Cardiology</em>, <em>29</em>, 7396–7396.</p></li>
<li><p>Lincoff, A., Mark, D., Califf, R., Tcheng, J., Ellis, S.,
DavidsonRay, L., Anderson, K., Stoner, G., &amp; Topol, E. (1997). Economic
assessment of platelet glycoprotein IIb/IIa receptor blockade during
coronary intervention in the EPILOG trial. <em>Journal of the American
College of Cardiology</em>, <em>29</em>, 97484–97484.</p></li>
<li><p>Lincoff, A. M., Califf, R. M., Anderson, K. M., Weisman, H. F.,
Aguirre, F. V., Kleiman, N. S., Harrington, R. A., Topol, E. J., &amp;
investigators, E. (1997). Evidence for prevention of death and
myocardial infarction with platelet membrane glycoprotein IIb/IIIa
receptor blockade by abciximab (<span class="nocase">c7E3 Fab</span>)
among patients with unstable angina undergoing percutaneous coronary
revascularization. <em>Journal of the American College of Cardiology</em>,
<em>30</em>(1), 149–156.</p></li>
<li><p>Lincoff, A. M., Tcheng, J. E., Califf, R. M., Bass, T., Popma, J.
J., Teirstein, P. S., Kleiman, N. S., Hattel, L. J., Anderson, H. V.,
Ferguson, J. J., et al. (1997). Standard versus low-dose weight-adjusted
heparin in patients treated with the platelet glycoprotein IIb/IIIa
receptor antibody fragment abciximab (<span class="nocase">c7E3
Fab</span>) during percutaneous coronary revascularization. <em>The
American Journal of Cardiology</em>, <em>79</em>(3), 286–291.</p></li>
<li><p>Mak, K.-H., Challapalli, R., Eisenberg, M. J., Anderson, K. M.,
Califf, R. M., Topol, E. J., investigators, E., et al. (1997). Effect of
platelet glycoprotein IIb/IIIa receptor inhibition on distal
embolization during percutaneous revascularization of aortocoronary
saphenous vein grafts. <em>The American Journal of Cardiology</em>, <em>80</em>(8),
985–988.</p></li>
<li><p>Topol, E. J., Ferguson, J. J., Weisman, H. F., Tcheng, J. E.,
Ellis, S. G., Kleiman, N. S., Ivanhoe, R. J., Wang, A. L., Miller, D.
P., Anderson, K. M., et al. (1997). Long-term protection from myocardial
ischemic events in a randomized trial of brief integrin <em>β</em><!-- -->3
blockade with percutaneous coronary intervention. <em>JAMA</em>, <em>278</em>(6),
479–484.</p></li>
</ul>
</div>
<div id="section-18" class="section level2">
<h2>1996</h2>
<ul>
<li><p>Coller, B. S., Anderson, K. M., &amp; Weisman, H. F. (1996). The
anti-GPIIb-IIIa agents: Fundamental and clinical aspects.
<em>Pathophysiology of Haemostasis and Thrombosis</em>, <em>26</em>(Suppl. 4),
285–293.</p></li>
<li><p>Lefkovits, J., Ivanhoe, R. J., Califf, R. M., Bergelson, B. A.,
Anderson, K. M., Stoner, G. L., Weisman, H. F., Topol, E. J.,
Investigators, G. E., et al. (1996). Effects of platelet glycoprotein
IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab)
on acute and six-month outcomes after percutaneous transluminal coronary
angioplasty for acute myocardial infarction. <em>The American Journal of
Cardiology</em>, <em>77</em>(12), 1045–1051.</p></li>
<li><p>Mark, D. B., Talley, J. D., Topol, E. J., Bowman, L., Lam, L. C.,
Anderson, K. M., Jollis, J. G., Cleman, M. W., Lee, K. L., Aversano, T.,
et al. (1996). Economic assessment of platelet glycoprotein IIb/IIIa
inhibition for prevention of ischemic complications of high-risk
coronary angioplasty. <em>Circulation</em>, <em>94</em>(4), 629–635.</p></li>
</ul>
</div>
<div id="section-19" class="section level2">
<h2>1995</h2>
<ul>
<li><p>Aguirre, F. V., Topol, E. J., Ferguson, J. J., Anderson, K.,
Blankenship, J. C., Heuser, R. R., Sigmon, K., Taylor, M., Gottlieb, R.,
Hanovich, G., et al. (1995). Bleeding complications with the chimeric
antibody to platelet glycoprotein IIb/IIIa integrin in patients
undergoing percutaneous coronary intervention. <em>Circulation</em>, <em>91</em>(12),
2882–2890.</p></li>
<li><p>Coller, B. S., Anderson, K., &amp; Weisman, H. F. (1995). New
antiplatelet agents: Platelet GPIIb/IIIa antagonists. <em>Thrombosis and
Haemostasis</em>, <em>74</em>(07), 302–308.</p></li>
<li><p>Lauer, M. S., Okin, P. M., Anderson, K. M., &amp; Levy, D. (1995).
Impact of echocardiographic left ventricular mass on mechanistic
implications of exercise testing parameters. <em>The American Journal of
Cardiology</em>, <em>76</em>(12), 952–956.</p></li>
<li><p>Moliterno, D. J., Califf, R. M., Aguirre, F. V., Anderson, K.,
Sigmon, K. N., Weisman, H. F., Topol, E. J., EPIC Study Investigators,
et al. (1995). Effect of platelet glycoprotein IIb/IIIa integrin
blockade on activated clotting time during percutaneous transluminal
coronary angioplasty or directional atherectomy (the EPIC trial). <em>The
American Journal of Cardiology</em>, <em>75</em>(8), 559–562.</p></li>
<li><p>Weisman, H., Schaible, T., Jordan, R., Cabot, C., &amp; Anderson, K.
(1995). Anti-platelet monoclonal antibodies for the prevention of
arterial thrombosis: Experience with ReoPro, a monoclonal antibody
directed against the platelet GPIIb/IIIa receptor. <em>Biochemical Society
Transactions</em>, <em>23</em>(4), 1051–1057.</p></li>
</ul>
</div>
<div id="section-20" class="section level2">
<h2>1994</h2>
<ul>
<li><p>Cole, B. F., Gelber, R. D., &amp; Anderson, K. M. (1994). Parametric
approaches to quality-adjusted survival analysis. <em>Biometrics</em>, 621–631.</p></li>
<li><p>The EPIC Investigators. (1994). Use of a monoclonal antibody
directed against the platelet glycoprotein IIb/IIIa receptor in
high-risk coronary angioplasty. <em>New England Journal of Medicine</em>,
<em>330</em>(14), 956–961.</p></li>
<li><p>Lauer, M. S., Anderson, K. M., Larson, M. G., &amp; Levy, D. (1994). A
new method for indexing left ventricular mass for differences in body
size. <em>The American Journal of Cardiology</em>, <em>74</em>(5), 487–491.</p></li>
<li><p>Lefkovits, J., Anderson, K., Weisman, H., &amp; Topol, E. (1994).
Increased risk of non-Q MI following DCA: Evidence for a platelet
dependent mechanism from the EPIC trial. <em>Circulation</em>, <em>90</em>, 214–214.</p></li>
<li><p>Lefkovits, J., Ivanhoe, R., Anderson, K., Weisman, H., &amp; Topol, E.
(1994). Platelet-IIb/IIIa receptor inhibition during PTCA for acute
myocardial-infarction—insights from the EPIC trial. <em>Circulation</em>, <em>90</em>,
564–564.</p></li>
<li><p>Odell, P. M., Anderson, K. M., &amp; Kannel, W. B. (1994). New models
for predicting cardiovascular events. <em>Journal of Clinical
Epidemiology</em>, <em>47</em>(6), 583–592.</p></li>
<li><p>Topol, E., Califf, R., Weisman, H., Ellis, S., Tcheng, J., Worley,
S., Ivanhoe, R., George, B., Fintel, D., Weston, M., et al. (1994).
Randomised trial of coronary intervention with antibody against platelet
IIb/IIIa iritegrin for reduction of clinical restenosis: Results at six
months. <em>The Lancet</em>, <em>343</em>(8902), 881–886.</p></li>
<li><p>Wilson, P. W., Anderson, K. M., Harri, T., Kannel, W. B., &amp;
Castelli, W. P. (1994). Determinants of change in total cholesterol and
HDL-C with age: The framingham study. <em>Journal of Gerontology</em>, <em>49</em>(6),
M252–M257.</p></li>
</ul>
</div>
<div id="section-21" class="section level2">
<h2>1993</h2>
<ul>
<li><p>Ellis, S. G., Tcheng, J. E., Navetta, F. I., Muller, D., Weisman,
H. F., Smith, C., Anderson, K. M., Califf, R. M., &amp; Topol, E. J. (1993).
Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab
directed against platelet glycoprotein IIb/IIIa in patients undergoing
elective coronary angioplasty. <em>Coronary Artery Disease</em>, <em>4</em>(2),
167–175.</p></li>
<li><p>Ho, K., Anderson, K. M., Kannel, W. B., Grossman, W., &amp; Levy, D.
(1993). Survival after the onset of congestive heart failure in
framingham heart study subjects. <em>Circulation</em>, <em>88</em>(1), 107–115.</p></li>
</ul>
</div>
<div id="section-22" class="section level2">
<h2>1992</h2>
<ul>
<li><p>Anderson, K. M., &amp; Kannel, W. B. (1992). Obesity and disease. In P.
Björntorp &amp; B. Brodoff (Eds.), <em>Obesity</em> (pp. 465–473). JB Lippincott
Company.</p></li>
<li><p>Benjamin, E. J., Levy, D., Anderson, K. M., Wolf, P. A., Plehn, J.
F., Evans, J. C., Comai, K., Fuller, D. L., &amp; Sutton, M. S. J. (1992).
Determinants of doppler indexes of left ventricular diastolic function
in normal subjects (the framingham heart study). <em>The American Journal
of Cardiology</em>, <em>70</em>(4), 508–515.</p></li>
<li><p>Berger, C. J., Murabito, J. M., Evans, J. C., Anderson, K. M., &amp;
Levy, D. (1992). Prognosis after first myocardial infarction: Comparison
of Q-wave and non-Q-wave myocardial infarction in the Framingham Heart
Study. <em>JAMA</em>, <em>268</em>(12), 1545–1551.</p></li>
<li><p>Castelli, W. P., Anderson, K., Wilson, P. W., &amp; Levy, D. (1992).
Lipids and risk of coronary heart disease the framingham study. <em>Annals
of Epidemiology</em>, <em>2</em>(1-2), 23–28.</p></li>
<li><p>Genest Jr, J., McNamara, J. R., Ordovas, J. M., Jenner, J. L.,
Silberman, S. R., Anderson, K. M., Wilson, P. W., Salem, D. N., &amp;
Schaefer, E. J. (1992). Lipoprotein cholesterol, apolipoprotein A-I and
B and lipoprotein (a) abnormalities in men with premature coronary
artery disease. <em>Journal of the American College of Cardiology</em>,
<em>19</em>(4), 792–802.</p></li>
<li><p>Kannel, W., Anderson, K., &amp; Evans, J. (1992). Relevance of blood
lipids in the elderly: The framingham study. <em>Cardiovasc Risk Factors</em>,
<em>2</em>, 170–179.</p></li>
<li><p>Kannel, W. B., Anderson, K., &amp; Wilson, P. W. (1992). White blood
cell count and cardiovascular disease: Insights from the framingham
study. <em>JAMA</em>, <em>267</em>(9), 1253–1256.</p></li>
<li><p>Kreger, B. E., Anderson, K. M., Schatzkin, A., &amp; Splansky, G. L.
(1992). Serum cholesterol level, body mass index, and the risk of colon
cancer. The framingham study. <em>Cancer</em>, <em>70</em>(5), 1038–1043.</p></li>
<li><p>Lauer, M. S., Anderson, K. M., &amp; Levy, D. (1992). Separate and
joint influences of obesity and mild hypertension on left ventricular
mass and geometry: The framingham heart study. <em>Journal of the American
College of Cardiology</em>, <em>19</em>(1), 130–134.</p></li>
<li><p>Lauer, M. S., Levy, D., Anderson, K. M., &amp; Plehn, J. F. (1992). Is
there a relationship between exercise systolic blood pressure response
and left ventricular mass? The framingham heart study. <em>Annals of
Internal Medicine</em>, <em>116</em>(3), 203–210.</p></li>
<li><p>Levy, D., Murabito, J. M., Anderson, K. M., Christiansen, J. C., &amp;
Castelli, W. P. (1992). Echocardiographic left ventricular hypertrophy:
Clinical characteristics. The framingham heart study. <em>Clinical and
Experimental Hypertension. Part A: Theory and Practice</em>, <em>14</em>(1-2),
85–97.</p></li>
<li><p>O’Leary, D. H., Anderson, K. M., Wolf, P. A., Evans, J. C., &amp;
Poehlman, H. W. (1992). Cholesterol and carotid atherosclerosis in older
persons: The framingham study. <em>Annals of Epidemiology</em>, <em>2</em>(1-2),
147–153.</p></li>
<li><p>Odell, P. M., Anderson, K. M., &amp; D’Agostino, R. B. (1992). Maximum
likelihood estimation for interval-censored data using a Weibull-based
accelerated failure time model. <em>Biometrics</em>, 951–959.</p></li>
<li><p>Singer, D. E., Nathan, D. M., Anderson, K. M., Wilson, P. W., &amp;
Evans, J. C. (1992). Association of <em>H<strong>b</strong>A</em><sub>1<em>c</em></sub> with
prevalent cardiovascular disease in the original cohort of the
framingham heart study. <em>Diabetes</em>, <em>41</em>(2), 202–208.</p></li>
</ul>
</div>
<div id="section-23" class="section level2">
<h2>1991</h2>
<ul>
<li><p>Anderson, K. M., Odell, P. M., Wilson, P. W., &amp; Kannel, W. B.
(1991). Cardiovascular disease risk profiles. <em>American Heart Journal</em>,
<em>121</em>(1), 293–298.</p></li>
<li><p>Anderson, K. M. (1991). A nonproportional hazards weibull
accelerated failure time regression model. <em>Biometrics</em>, 281–288.</p></li>
<li><p>Anderson, K. M., Wilson, P., Odell, P. M., &amp; Kannel, W. B. (1991).
An updated coronary risk profile. A statement for health professionals.
<em>Circulation</em>, <em>83</em>(1), 356–362.</p></li>
<li><p>Galderisi, M., Anderson, K. M., Wilson, P. W., &amp; Levy, D. (1991).
Echocardiographic evidence for the existence of a distinct diabetic
cardiomyopathy (the framingham heart study). <em>The American Journal of
Cardiology</em>, <em>68</em>(1), 85–89.</p></li>
<li><p>Goldberg, R. J., Bengtson, J., Chen, Z., Anderson, K. M., Locati,
E., &amp; Levy, D. (1991). Duration of the QT interval and total and
cardiovascular mortality in healthy persons (the framingham heart study
experience). <em>The American Journal of Cardiology</em>, <em>67</em>(1), 55–58.</p></li>
<li><p>Kreger, B. E., Anderson, K. M., &amp; Levy, D. (1991). QRS interval
fails to predict coronary disease incidence: The framingham study.
<em>Archives of Internal Medicine</em>, <em>151</em>(7), 1365–1368.</p></li>
<li><p>Lauer, M. S., Anderson, K. M., Kannel, W. B., &amp; Levy, D. (1991).
The impact of obesity on left ventricular mass and geometry: The
framingham heart study. <em>JAMA</em>, <em>266</em>(2), 231–236.</p></li>
<li><p>Lauer, M. S., Anderson, K. M., &amp; Levy, D. (1991). Influence of
contemporary versus 30-year blood pressure levels on left ventricular
mass and geometry: The framingham heart study. <em>Journal of the American
College of Cardiology</em>, <em>18</em>(5), 1287–1294.</p></li>
<li><p>Okin, P. M., Anderson, K., Levy, D., &amp; Kligfield, P. (1991). Heart
rate adjustment of exercise-induced ST segment depression. Improved risk
stratification in the framingham offspring study. <em>Circulation</em>,
<em>83</em>(3), 866–874.</p></li>
<li><p>Silberfarb, P. M., Anderson, K. M., Rundle, A. C., Holland, J.,
Cooper, M. R., &amp; McIntyre, O. (1991). Mood and clinical status in
patients with multiple myeloma. <em>Journal of Clinical Oncology</em>, <em>9</em>(12),
2219–2224.</p></li>
<li><p>Wilson, P. W., Anderson, K. M., &amp; Castelli, W. (1991). The impact
of triglycerides on coronary heart disease: The framingham study.
<em>Athero Rev</em>, <em>22</em>, 59–63.</p></li>
<li><p>Wilson, P. W., Anderson, K. M., Castelli, W. P., &amp; Kannel, W. B.
(1991). Twelve-year incidence of coronary heart disease in middle-aged
adults during the era of hypertensive therapy: The framingham offspring
study. <em>The American Journal of Medicine</em>, <em>90</em>(1), 11–16.</p></li>
</ul>
</div>
<div id="section-24" class="section level2">
<h2>1990</h2>
<ul>
<li><p>Ballard-Barbash, R., Schatzkin, A., Carter, C. L., Kannel, W. B.,
Kreger, B. E., D’Agostino, R. B., Splansky, G. L., Anderson, K. M., &amp;
Helsel, W. E. (1990). Body fat distribution and breast cancer in the
framingham study. <em>JNCI: Journal of the National Cancer Institute</em>,
<em>82</em>(4), 286–290.</p></li>
<li><p>Ballard-Barbash, R., Schatzkin, A., Albanes, D., Schiffman, M. H.,
Kreger, B. E., Kannel, W. B., Anderson, K. M., &amp; Helsel, W. E. (1990).
Physical activity and risk of large bowel cancer in the framingham
study. <em>Cancer Research</em>, <em>50</em>(12), 3610–3613.</p></li>
<li><p>D’Agostino, R. B., Lee, M.-L., Belanger, A. J., Cupples, L. A.,
Anderson, K., &amp; Kannel, W. B. (1990). Relation of pooled logistic
regression to time dependent cox regression analysis: The framingham
heart study. <em>Statistics in Medicine</em>, <em>9</em>(12), 1501–1515.</p></li>
<li><p>Jones, M. G., Anderson, K. M., Wilson, P. W., Kannel, W. B.,
Wagner, N. B., &amp; Wagner, G. S. (1990). Prognostic use of a QRS scoring
system after hospital discharge for initial acute myocardial infarction
in the framingham cohort. <em>The American Journal of Cardiology</em>, <em>66</em>(5),
546–550.</p></li>
<li><p>Kaufman, H. W., McNamara, J. R., Anderson, K. M., Wilson, P. W., &amp;
Schaefer, E. J. (1990). How reliably can compact chemistry analyzers
measure lipids? <em>JAMA</em>, <em>263</em>(9), 1245–1249.</p></li>
<li><p>Levy, D., Labib, S. B., Anderson, K. M., Christiansen, J. C.,
Kannel, W. B., &amp; Castelli, W. P. (1990). Determinants of sensitivity and
specificity of electrocardiographic criteria for left ventricular
hypertrophy. <em>Circulation</em>, <em>81</em>(3), 815–820.</p></li>
<li><p>Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., &amp;
Castelli, W. P. (1990). Prognostic implications of echocardiographically
determined left ventricular mass in the framingham heart study. <em>New
England Journal of Medicine</em>, <em>322</em>(22), 1561–1566.</p></li>
<li><p>Levy, D., Wilson, P. W., Anderson, K. M., &amp; Castelli, W. P.
(1990). Stratifying the patient at risk from coronary disease: New
insights from the framingham heart study. <em>American Heart Journal</em>,
<em>119</em>(3), 712–717.</p></li>
<li><p>Murabito, J. M., Anderson, K. M., Kannel, W. B., Evans, J. C., &amp;
Levy, D. (1990). Risk of coronary heart disease in subjects with chest
discomfort: The framingham heart study. <em>The American Journal of
Medicine</em>, <em>89</em>(3), 297–302.</p></li>
</ul>
</div>
<div id="section-25" class="section level2">
<h2>1989</h2>
<ul>
<li><p>Castelli, W. P., Wilson, P. W., Levy, D., &amp; Anderson, K. (1989).
Cardiovascular risk factors in the elderly. <em>The American Journal of
Cardiology</em>, <em>63</em>(16), 12–19.</p></li>
<li><p>Kreger, B. E., Anderson, K. M., &amp; Kannel, W. B. (1989). Prevalence
of intraventricular block in the general population: The framingham
study. <em>American Heart Journal</em>, <em>117</em>(4), 903–910.</p></li>
<li><p>Preisler, H., Anderson, K., Rai, K., Cuttner, J., Yates, J.,
DuPre, E., &amp; Holland, J. (1989). The frequency of long-term remission in
patients with acute myelogenous leukaemia treated with conventional
maintenance chemotherapy: A study of 760 patients with a minimal
follow-up time of 6 years. <em>British Journal of Haematology</em>, <em>71</em>(2),
189–194.</p></li>
<li><p>Schatzkin, A., Carter, C. L., Green, S. B., Kreger, B. E.,
Splansky, G. L., Anderson, K. M., Helsel, surname, &amp; Kannel, W. B.
(1989). Is alcohol consumption related to breast cancer? Results from
the framingham heart study. <em>JNCI: Journal of the National Cancer
Institute</em>, <em>81</em>(1), 31–35.</p></li>
<li><p>Wilson, P. W., Christiansen, J. C., Anderson, K. M., &amp; Kannel, W.
B. (1989). Impact of national guidelines for cholesterol risk factor
screening: The framingham offspring study. <em>JAMA</em>, <em>262</em>(1), 41–44.</p></li>
</ul>
</div>
<div id="section-26" class="section level2">
<h2>1988</h2>
<ul>
<li><p>Cupples, L. A., D’Agostino, R. B., Anderson, K., &amp; Kannel, W. B.
(1988). Comparison of baseline and repeated measure covariate techniques
in the framingham heart study. <em>Statistics in Medicine</em>, <em>7</em>(1-2),
205–218.</p></li>
<li><p>Hands, M. E., Sia, S. B., Shook, T. L., Anderson, K., Stone, P.
H., Levy, D., Castelli, W. P., Rutherford, J. D., Group, F. H. S., et
al. (1988). Silent myocardial ischemia in asymptomatic survivors of
unrecognized myocardial infarction and matched controls. <em>American Heart
Journal</em>, <em>116</em>(6), 1488–1492.</p></li>
<li><p>Levy, D., Anderson, K. M., Christiansen, J. C., Campanile, G., &amp;
Stokes III, J. (1988). Antihypertensive drug therapy and arrhythmia
risk. <em>The American Journal of Cardiology</em>, <em>62</em>(1), 147–149.</p></li>
<li><p>Levy, D., Anderson, K. M., Savage, D. D., Kannel, W. B.,
Christiansen, J. C., &amp; Castelli, W. P. (1988). Echocardiographically
detected left ventricular hypertrophy: Prevalence and risk factors: The
framingham heart study. <em>Annals of Internal Medicine</em>, <em>108</em>(1), 7–13.</p></li>
<li><p>OLEARY, D., Anderson, K., Kase, C., Wolf, P., &amp; Kannel, W. (1988).
Extracranial carotid atherosclerosis in a general population—the
framingham study. <em>Stroke</em>, <em>19</em>, 143–143.</p></li>
</ul>
</div>
<div id="section-27" class="section level2">
<h2>1987</h2>
<ul>
<li><p>Anderson, K. M., Castelli, W. P., &amp; Levy, D. (1987). Cholesterol
and mortality: 30 years of follow-up from the framingham study. <em>JAMA</em>,
<em>257</em>(16), 2176–2180.</p></li>
<li><p>Anderson, K. M., Wilson, P. W., Garrison, R. J., &amp; Castelli, W. P.
(1987). Longitudinal and secular trends in lipoprotein cholesterol
measurements in a general population sample the framingham offspring
study. <em>Atherosclerosis</em>, <em>68</em>(1-2), 59–66.</p></li>
<li><p>Kannel, W. B., Anderson, K., McGee, D. L., Degatano, L. S., &amp;
Stampfer, M. J. (1987). Nonspecific electrocardiographic abnormality as
a predictor of coronary heart disease: The framingham study. <em>American
Heart Journal</em>, <em>113</em>(2), 370–376.</p></li>
<li><p>Levy, D., Savage, D. D., Garrison, R. J., Anderson, K. M., Kannel,
W. B., &amp; Castelli, W. P. (1987). Echocardiographic criteria for left
ventricular hypertrophy: The framingham heart study. <em>The American
Journal of Cardiology</em>, <em>59</em>(9), 956–960.</p></li>
<li><p>Levy, D., Anderson, K. M., Plehn, J., Savage, D. D., Christiansen,
J. C., &amp; Castelli, W. P. (1987). Echocardiographically determined left
ventricular structural and functional correlates of complex or frequent
ventricular arrhythmias on one-hour ambulatory electrocardiographic
monitoring. <em>The American Journal of Cardiology</em>, <em>59</em>(8), 836–840.</p></li>
<li><p>Levy, D., Anderson, K., Savage, D., Kannel, W., &amp; Castelli, W.
(1987). Influence of 30 year mean blood-pressure levels on
left-ventricular mass—the framingham heart study. <em>Journal of the
American College of Cardiology</em>, <em>9</em>, A115–A115.</p></li>
<li><p>Levy, D., Anderson, K. M., Savage, D. D., Balkus, S. A., Kannel,
W. B., &amp; Castelli, W. P. (1987). Risk of ventricular arrhythmias in left
ventricular hypertrophy: The framingham heart study. <em>The American
Journal of Cardiology</em>, <em>60</em>(7), 560–565.</p></li>
<li><p>O’Connor, G., Anderson, K., Kannel, W., Brand, F., Christiansen,
J., Weiss, S., &amp; Speizer, F. (1987). Prevalence and prognosis of dyspnea
in the framingham study. <em>Chest</em>, <em>92</em>(Suppl 2), 90S.</p></li>
</ul>
</div>
<div id="section-28" class="section level2">
<h2>1986</h2>
<ul>
<li><p>Castelli, W. P., &amp; Anderson, K. (1986). A population at risk:
Prevalence of high cholesterol levels in hypertensive patients in the
framingham study. <em>The American Journal of Medicine</em>, <em>80</em>(2), 23–32.</p></li>
<li><p>Olson, W., Bennett, T., Huberty, K., &amp; Anderson, K. (1986).
Automatic detection of ventricular-fibrillation with chronically
implanted pressure sensors. <em>Journal of the American College of
Cardiology</em>, <em>7</em>, A182–A182.</p></li>
<li><p>Sharma, A., Sutton, R., Bennett, T., KLEIN, G., ANDERSON, K., &amp;
BECK, R. (1986). Physiological pacing based on beat-to-beat measurement
of right ventricular dp-dt max-initial feasibility studies in man.
<em>Journal of the American College of Cardiology</em>, <em>7</em>, A3–A3.</p></li>
<li><p>Wilson, P. W., Anderson, K. M., &amp; Kannel, W. B. (1986).
Epidemiology of diabetes mellitus in the elderly: The framingham study.
<em>The American Journal of Medicine</em>, <em>80</em>(5), 3–9.</p></li>
</ul>
</div>
<div id="section-29" class="section level2">
<h2>1985</h2>
<ul>
<li><p>Bennett, T., Baudino, M., Bornzin, G., Anderson, K., &amp; Olson, W.
(1985). Rate-responsive pacing using dynamic right ventricular pressure
in heart-blocked dogs. <em>Journal of the American College of Cardiology</em>,
<em>5</em>, 393–393.</p></li>
<li><p>Levy, D., Savage, D., Garrison, R., Balkus, S., Anderson, K.,
Kannel, W., &amp; Castelli, W. (1985). The association of left-ventricular
hypertrophy with ventricular arrhythmias—the framingham heart study.
<em>Circulation</em>, <em>72</em>, 46–46.</p></li>
<li><p>Sobol, R., Royston, I., LeBien, T., Minowada, J., Anderson, K.,
Davey, F., Cuttner, J., Schiffer, C., Ellison, R., &amp; Bloomfield, C.
(1985). Adult acute lymphoblastic leukemia phenotypes defined by
monoclonal antibodies. <em>Blood</em>, <em>65</em>(3), 730–735.</p></li>
<li><p>Whittemore, A. S., Paffenbarger Jr, R. S., Anderson, K., &amp; Lee, J.
E. (1985). Early precursors of site-specific cancers in college men and
women. <em>Journal of the National Cancer Institute</em>, <em>74</em>(1), 43–51.</p></li>
<li><p>Wilson, P., Kannel, W., &amp; Anderson, K. (1985). Lipids, glucose
intolerance and vascular disease: The framingham study. <em>Monographs on
Atherosclerosis</em>, <em>13</em>, 1–11.</p></li>
</ul>
</div>
<div id="section-30" class="section level2">
<h2>1984</h2>
<ul>
<li>Whittemore, A. S., Paffenbarger Jr, R. S., Anderson, K., &amp; Lee, J.
E. (1984). Early precursors of urogenital cancers in former college men.
<em>The Journal of Urology</em>, <em>132</em>(6), 1256–1261.</li>
</ul>
</div>
<div id="section-31" class="section level2">
<h2>1983</h2>
<ul>
<li><p>Anderson, K., Wilson, P., Garrison, R., &amp; Castelli, W. (1983).
Longitudinal and secular trends in lipoproteins: The framingham
offspring study. <em>Arterioscler Thromb</em>, <em>3</em>, 273–281.</p></li>
<li><p>Whittemore, A. S., Paffenbarger Jr, R. S., Anderson, K., &amp;
Halpern, J. (1983). Early precursors of pancreatic cancer in college
men. <em>Journal of Chronic Diseases</em>, <em>36</em>(3), 251–256.</p></li>
</ul>
</div>
<div id="section-32" class="section level2">
<h2>1982</h2>
<ul>
<li><p>Anderson, K., Sobel, M., &amp; Uppuluri, V. (1982). Quota fulfillment
times. <em>Canadian Journal of Statistics</em>, <em>10</em>(2), 73–88.</p></li>
<li><p>Whittemore, A. S., McLarty, J. W., Fortson, N., &amp; Anderson, K.
(1982). Regression analysis of cytopathological data. <em>Biometrics</em>,
899–905.</p></li>
</ul>
</div>

    </div>
  </article>

  


</main>

      <footer class="footer">
        <ul class="footer-links">
          <li>
            <a href="/index.xml" type="application/rss+xml" target="_blank">RSS feed</a>
          </li>
        </ul>
      </footer>

    </div>
    

    

    
  </body>
</html>

